Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA)

American Heart Journal

Volumn 169, Issue 3, 2015, Pages 387-395.e3

  Yeboah, Joseph ^a   Sillau, Stefan ^b   Delaney, Joseph C ^b   Blaha, Michael J ^c   Michos, Erin D ^c   Young, Rebekah ^b   Qureshi, Waqas T ^a   McClelland, Robyn ^b   Burke, Gregory L ^a   Psaty, Bruce M ^d,e   Herrington, David M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; AMERICAN COLLEGE OF CARDIOLOGY AMERICAN HEART ASSOCIATION CHOLESTEROL GUIDELINE; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DRUG USE; ETHNICITY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ETHNOLOGY; MIDDLE AGED; RISK ASSESSMENT; RISK FACTOR; STANDARDS;

AGED; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS;

EID: 84926152401     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.12.018     Document Type: Article

References (27)

1. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
2. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
3. N.J. Stone, J. Robinson, and A.H. Lichtenstein 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol S0735-1097 13 2013 06028-2
4. J. Lenzer Majority of panelists on controversial new cholesterol guideline have current or recent ties to drug manufacturers BMJ 347 2013 f6989
5. P.M. Ridker, and N.R. Cook Statins: new American guidelines for prevention of cardiovascular disease Lancet 382 2013 1762 1765
6. P. Muntner, M.M. Safford, and M. Cushman Comment on the reports of over-estimation of ASCVD risk using the 2013 ACC/AHA risk equation Circulation 129 2014 266 267
7. J.P.A. Ioannidis More than a billion people taking statins? Potential implications of the new cardiovascular guidelines JAMA 311 2014 463 464
8. F. Taylor, M.D. Huffman, and A.F. Macedo Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev 1 2013 10.1002/14651858.CD004816 [Art. No.: CD004816]
9. Taylor, C. Fiona, Huffman, Mark, Ebrahim, and Shah Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA Clinical Evidence Synposis JAMA 310 2013 2451 2452
10. Peter S. Server, Bijorn Dahlof, and Neil R. Poulter Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial Lancet 361 2003 1149 1158
11. E.J. Mills, B. Rachlis, and P. Wu Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients J Am Coll Cardiol 52 2008 1769 1781
12. N. Sattar, D. Preiss, and H.M. Murray Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
13. D. Preiss, S.R. Seshasai, and P. Welsh Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
14. P.M. Ridker, E. Danielson, and F.A. Fonsca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 358 2008 2195 2207
15. S.N. Raipathak, D.J. Kumbhani, and J. Crandall Statin therapy and risk of developing type 2 diabetes. A meta analysis Diabetes Care 32 2009 1924 1929
16. James S. Floyd, Susan R. Heckbert, and Noel S. Weiss Use of administrative data to estimate the incidence of statin-related rhabdomyolysis JAMA 307 2012 1580 1582
17. D.E. Bild, D.A. Bluemke, and G.L. Burke Multi-Ethnic Study of Atherosclerosis: objectives and design Am J Epidemiol 156 2002 871 881
18. M.J. Pencina, A.M. Navar-Boggan, and R.B. D'Agostino Application of new cholesterol guidelines to a population- based sample N Engl J Med 370 2014 1422 1431
19. R.B. D'Agostino Sr., S. Grundy, and L.M. Sullivan Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation JAMA 286 2001 180 187
20. D.C. Goff Jr., D.M. Lloyd-Jones, and G. Bennett 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol S0735-1097 13 2013 06031 06032
21. C.N. Bang, and P.M. Okin Statin treatment, new onset diabetes and other adverse effects, a systematic review Curr Cardiol Rep 16 2014 461 464
22. J.J. Ellis, S.R. Erickson, and J.G. Stevenson Suboptimal statin adherence and discontinuation in primary and secondary prevention J Gen Intern Med 19 2004 638 645
23. C.A. Jackevicius, M. Mamdani, and J.V. Tu Adherence with statin therapy in elderly patients with and without acute coronary syndromes JAMA 288 2002 462 467
24. M.Y. Wei, M.K. Ito, and J.D. Cohen Predictors of statin adherence, switching and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education J Clin Lipidol 7 2013 472 483
25. P. Muntner, L.D. Colantonio, and M. Cushman Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations JAMA 311 2014 1406 1415
26. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
27. J. Yeboah, A.R. Folsom, and G.L. Burke Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the Multi-Ethnic Study of Atherosclerosis Circulation 120 2009 502 509